April 28, 2020 / 8:54 PM / a month ago

BRIEF-Dynavax Reports Interim Analysis Of Ongoing Clinical Trial Evaluating Heplisav-B In Patients Undergoing Hemodialysis

April 28 (Reuters) - Dynavax Technologies Corp:

* DYNAVAX REPORTS INTERIM ANALYSIS OF ONGOING CLINICAL TRIAL EVALUATING HEPLISAV-B IN PATIENTS UNDERGOING HEMODIALYSIS

* DYNAVAX TECHNOLOGIES CORP - SAFETY DATA SHOWED HEPLISAV-B WAS WELL TOLERATED

* DYNAVAX TECHNOLOGIES CORP - DEMONSTRATED SEROPROTECTION RATE OF 86.4% AT WEEK 20 AFTER 4 STANDARD DOSES OF HEPLISAV-B

* DYNAVAX TECHNOLOGIES - FULL STUDY DATA FROM HEPLISAV-B STUDY ANTICIPATED IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below